---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-291992"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2025-11-24T23:59:59+00:00"
generated_at: "2026-05-16T17:21:15.372773+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Invivyd selects RSV antibody candidate VBY329; 2H 2026 IND readiness targeted

## Summary
- VBY329 showed 1.5x greater potency vs nirsevimab, 1.2x vs clesrovimab against authentic RSV strains.
- Up to ~500-fold enhanced neutralization vs nirsevimab-resistant variants in pseudovirus assays.
- Half-life extension technology expected to expand protective window vs standard of care.
- Pediatric RSV prophylaxis market estimated $3-4B annually globally by 2030.
- Additional discovery efforts for ultra-long half-life RSV antibodies for elderly/immunocompromised.

## SEC filing metadata
- accession: 0001193125-25-291992
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2025-11-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000119312525291992/0001193125-25-291992-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000119312525291992/ivvd-20251124.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-291992
- JSON: https://secwatch.observer/filing/0001193125-25-291992.json
- Plain text: https://secwatch.observer/filing/0001193125-25-291992.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.